Your session is about to expire
← Back to Search
AB308 + Zimberelimab for Advanced Cancers (ARC-12 Trial)
ARC-12 Trial Summary
This trial is testing a new combination therapy to see if it is safe and effective in treating advanced malignancies.
ARC-12 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARC-12 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARC-12 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs and bone marrow are working well.I can sign and follow the study's consent form and rules.I am 18 years or older and can legally consent to participate.I have not needed treatment for an autoimmune disease in the last 3 years.I am fully active or restricted in physically strenuous activity but can do light work.I stopped immunotherapy due to severe side effects.I have not had major surgery or serious injury in the last 28 days.I have been treated with an anti-TIGIT antibody before.I haven't taken any cancer drugs or been in a drug study in the last 28 days.
- Group 1: Dose Expansion Cohort 3
- Group 2: Dose Expansion Cohort 4
- Group 3: Dose Expansion Cohort 5
- Group 4: Dose Escalation Q3W Cohorts
- Group 5: Dose Escalation Q4W Cohorts
- Group 6: Dose Escalation Q6W Cohort
- Group 7: Dose Expansion Cohort 1
- Group 8: Dose Expansion Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there openings still available for participants of this investigation?
"According to clinicaltrials.gov, this research project remains open for patient recruitment. The trial was first listed on March 19th 2021 and has since undergone multiple revisions up until November 21st 2022."
Are there known health risks associated with AB308 ingestion?
"Due to the limited data surrounding AB308's safety and efficacy, we at Power deemed it a 1 on our risk scale."
In what locations can one access this research?
"Patients are being recruited for this trial at multiple sites, including AdventHealth Orlando in Aurora, Colorado; University of Colorado - Cancer Center - PPDS in Phoenix, Arizona; and Mayo Clinic Arizona - Mayo Clinic Hospital in Augusta, Georgia. In total there are 30 facilities taking part."
Share this study with friends
Copy Link
Messenger